Penn study demonstrates new way to boost immune memory — Cancer vaccine efficacy enhanced using anti-diabetic drug metformin. – University of Pennsylvania School of Medicine researchers have found that a common anti-diabetic drug might enhance the effectiveness of vaccines. The findings are described this week in an advanced online publication of Nature.
The global acceptance of COVID-19 vaccines increased from 75.2% in 2021 to 79.1% in 2022, according to a survey in 23 countries (including India) representing
A single dose of ChAdOx1 nCoV-19, an investigational vaccine against SARS-CoV-2, has protected six rhesus macaques from pneumonia caused by the virus, according to National
The U.S. Food and Drug Administration approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are
The U.S. Food and Drug Administration approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and
U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent
The U.S. Food and Drug Administration approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Praluent® (alirocumab) Injection, the first FDA-approved treatment in a new
Why some antidepressants may initially worsen symptoms – New research helps explain a paradoxical effect of certain antidepressants–that they may actually worsen symptoms before helping patients feel better. These findings may help investigators fix the problem as well as create new classes of drugs to treat depression.
New drug alirocumab halved number of heart attacks and strokes – An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, revealed by researchers at the European Society of Cardiology yearly gathering in Barcelona.
